CurrentRheuma
Get Weekly

Topic · page 24 of 47

Lupus & antiphospholipid syndrome

Systemic and cutaneous lupus erythematosus, lupus nephritis, neuropsychiatric lupus, disease activity, remission and low disease activity, damage, antimalarials and targeted treatment; antiphospholipid antibodies and antiphospholipid syndrome, thrombotic and obstetric

Briefs 921–960 of 1,848 placed here, newest publication first

Briefs in Lupus & antiphospholipid syndrome

Newest publication first

  1. Lupus Sci Med

    Unravelling the TCRβ repertoire: a key to unlocking the immunopathogenesis and precision medicine in SLE

    Case-control study

  2. Rheumatology (Oxford)

    Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria

    Diagnostic or prognostic study

  3. Lupus Sci Med

    EXamining the feasibility of exerCisE to manage symptoms of Lupus (EXCEL): a protocol for a randomised controlled pilot study

    Trial design

  4. Lupus

    Proportion, domains, and risk factors of cognitive impairment in systemic lupus erythematosus

    Cross-sectional study

  5. Lupus Sci Med

    Effect of Benson relaxation response technique on the quality of life among patients with systemic lupus erythematous: quasi-experimental study

    Mechanistic study

  6. Lupus Sci Med

    Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond

    Cross-sectional study

  7. Lupus

    Healthcare costs of systemic lupus erythematosus in New Zealand

    Cohort study

  8. Lupus Sci Med

    Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis

    Cohort study

  9. Rheumatology (Oxford)

    Menopausal hormone therapy and the risk of systemic lupus erythematosus and systemic sclerosis: a population-based nested case-control study

    Case-control study

  10. Arthritis Care Res (Hoboken)

    Measuring Frailty in Systemic Lupus Erythematosus

    Cohort study

  11. RMD Open

    Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study

    Cohort study

  12. Lupus Sci Med

    Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study

    Cohort study

  13. Lupus Sci Med

    Low versus high initial oral glucocorticoid dose for lupus nephritis: a pooled analysis of randomised controlled clinical trials

    Meta-analysis

  14. Lupus Sci Med

    Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA

    Cross-sectional study

  15. Lupus

    Utilisation patterns of immunomodulators and pregnancy outcomes in systemic lupus erythematosus: Insights from Korean national data

    Cohort study

  16. Lupus

    Urinary congophilia as a predictive biomarker of lupus nephritis in pregnant and non-pregnant women with systemic lupus erythematosus

    Diagnostic or prognostic study

  17. Ann Rheum Dis

    Evaluation and prediction of relapse risk in stable systemic lupus erythematosus patients after glucocorticoid withdrawal (PRESS): an open-label, multicentre, non-inferiority, randomised controlled study in China

    Randomized controlled trial

  18. Ann Rheum Dis

    Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders

    Mechanistic study

  19. RMD Open

    Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus

    Mechanistic study

  20. Arthritis Res Ther

    Risk prediction of new-onset thrombocytopenia in patients with systemic lupus erythematosus: a multicenter prospective cohort study based on Chinese SLE treatment and research group (CSTAR) registry

    Cohort study

  21. Lupus

    The effectiveness of telitacicept in patients with systemic lupus erythematosus: A retrospective, real-world study

    Cohort study

  22. Lupus Sci Med

    Real-world treatment patterns, healthcare resource utilisation and costs in patients with SLE in the USA

    Cohort study

  23. Semin Arthritis Rheum

    Impairment of white matter microstructure and structural network in patients with systemic lupus erythematosus

    Cross-sectional study

  24. Lupus

    Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus

    Cross-sectional study

  25. Lupus Sci Med

    Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups

    Randomized controlled trial

  26. Lupus

    2019 EULAR/ACR classification criteria for SLE score predicts future lupus hospital admission and costs

    Cohort study

  27. Rheumatology (Oxford)

    Renal arteriosclerosis in kidney biopsies associated with higher 10-year atherosclerotic cardiovascular disease in lupus nephritis

    Cohort study

  28. Rheumatology (Oxford)

    Improving the arthritis component of the SLEDAI-2K

    Secondary analysis

  29. Arthritis Res Ther

    Neutrophil extracellular traps and oxidative stress in systemic lupus erythematosus patients with and without renal involvement

    Cross-sectional study

  30. Arthritis Res Ther

    KLF2 controls the apoptosis of neutrophils and is associated with disease activity of systemic lupus erythematosus

    Mechanistic study

  31. Lancet Rheumatol

    Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study

    Cohort study

  32. Rheumatology (Oxford)

    Insights into the 2023 ACR/EULAR antiphospholipid syndrome classification criteria: findings from a cohort of 205 patients with primary APS

    Cohort study

  33. Clin Exp Rheumatol

    Application of the 2023 ACR/EULAR antiphospholipid syndrome classification criteria to patients fulfilling the 2006 revised Sapporo criteria

    Cross-sectional study

  34. Lupus Sci Med

    Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus

    Cohort study

  35. Rheumatology (Oxford)

    Cutaneous vasculitis in systemic lupus erythematosus: epidemiology and risk factors over a 20-year follow-up

    Cohort study

  36. Lupus Sci Med

    Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort

    Cohort study

  37. Lupus

    Clinical features and two-year outcomes in systemic lupus erythematosus patients with heart failure and reduced, mid-range and preserved ejection fractions

    Cohort study

  38. Lupus

    Early subclinical macular disease in asymptomatic patients with primary antiphospholipid syndrome: A quantitative multimodal retinal evaluation

    Cross-sectional study

  39. Lupus Sci Med

    Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA

    Cohort study

  40. Arthritis Rheumatol

    Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events, and Safety Outcomes in Patients With Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population‐Based Target Trial Emulation

    Cohort study

All 1,848 Briefs in ExploreShowing Briefs 921–960 of 1,848, newest first